Habot-Wilner Zohar, Sorkin Nir, Goldenberg Dafna, Goldstein Michaella
Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Retin Cases Brief Rep. 2015 Spring;9(2):151-3. doi: 10.1097/ICB.0000000000000122.
To describe a bilateral therapeutic effect of the 0.7-mg dexamethasone drug delivery system injected in 1 eye of a patient with bilateral, noninfectious uveitic macular edema and vitritis.
Interventional case report.
A 26-year-old woman had vitritis and macular edema in both eyes and received a dexamethasone drug delivery system injection to the right eye. Best-corrected visual acuity, clinical examination, and Heidelberg Spectralis spectral domain optical coherence tomography were performed at baseline and during follow-up visits. Follow-up time was 24 months. Vitritis and macular edema completely resolved in both eyes with bilateral improvement in visual acuity. Treatment effect enabled systemic immunosuppressive treatment to be lowered, and the effect lasted for 24 months.
Unilateral dexamethasone drug delivery system injection might have a bilateral therapeutic effect in uveitic eyes. This observation may be related to the compromised blood-retina barrier in eyes with uveitis. Further studies are warranted to assess this effect.
描述向一名患有双侧非感染性葡萄膜炎性黄斑水肿和葡萄膜炎的患者的一只眼睛注射0.7毫克地塞米松药物递送系统的双侧治疗效果。
介入性病例报告。
一名26岁女性双眼患有葡萄膜炎和黄斑水肿,右眼接受了地塞米松药物递送系统注射。在基线和随访期间进行了最佳矫正视力、临床检查和海德堡Spectralis光谱域光学相干断层扫描。随访时间为24个月。双眼的葡萄膜炎和黄斑水肿完全消退,视力得到双侧改善。治疗效果使全身免疫抑制治疗得以降低,且效果持续了24个月。
单侧注射地塞米松药物递送系统可能对葡萄膜炎性眼具有双侧治疗效果。这一观察结果可能与葡萄膜炎患者血视网膜屏障受损有关。有必要进行进一步研究以评估这种效果。